-
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Bianca Calì, Martina Troiani, Silvia Bressan, Giuseppe Attanasio, Sara Merler, Viola Moscarda, Simone Mosole, Elena Ricci, Christina Guo, Wei Yuan, Lewis Gallagher, Arian Lundberg, Ilona Bernett, Ines Figueiredo, Rydell Alvarez Arzola, Ernesto Bermudez Abreut, Mariantonietta D’Ambrosio, Nicolò Bancaro, Daniela Brina, Sara Zumerle, Andrea Alimonti
-
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Xueliang Wang, Yi Fang, Wei Liang, Chi Chun Wong, Huanlong Qin, Yaohui Gao, Meinong Liang, Lei Song, Yongxin Zhang, Miao Fan, Chuanfa Liu, Harry Cheuk-Hay Lau, Lixia Xu, Xiaoxing Li, Wu Song, Junlin Wang, Na Wang, Tao Yang, Mengmiao Mo, Xiang Zhang, Jun Yu
-
Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Yang Gao, Jianan Li, Wenfeng Cheng, Tian Diao, Huilan Liu, Yufei Bo, Chang Liu, Wei Zhou, Minmin Chen, Yuanyuan Zhang, Zhihua Liu, Weidong Han, Rufu Chen, Jirun Peng, Linnan Zhu, Wenhong Hou, Zemin Zhang
-
Ovarian cancer metastasis: Looking beyond the surface Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Emine Bayraktar, Sisy Chen, Sara Corvigno, Jinsong Liu, Anil K. Sood
Historically, ovarian cancer (OC) was thought to metastasize by surface-to-surface spread, but recent developments have yielded a new understanding of the paths of metastatic spread. Given the histologic and molecular heterogeneity of OC, we will focus on high-grade serous carcinoma (HGSC). Here, we provide a critical and more holistic view of the evidence supporting various routes of metastasis, including
-
From backstage to the spotlight: γδT cells in cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Robert Wiesheu, Seth B. Coffelt
γδT cells represent a group of immune cells that are understudied but whose utility has been recognized for cancer immunotherapy purposes. Recent studies have highlighted a critical role for these cells in tumor initiation, growth, and metastasis and revealed an increasingly complex biology of γδT cell subsets that is context and tissue specific. We discuss here how γδT cell subsets are regulated,
-
Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Siting Gan, Danilo G. Macalinao, Sayyed Hamed Shahoei, Lin Tian, Xin Jin, Harihar Basnet, Catherine Bibby, James T. Muller, Pranita Atri, Evan Seffar, Walid Chatila, Ali Karacay, Pharto Chanda, Anna-Katerina Hadjantonakis, Nikolaus Schultz, Edi Brogi, Tejus A. Bale, Nelson S. Moss, Rajmohan Murali, Dana Pe’er, Joan Massagué
-
Classifying cancer-associated fibroblasts—The good, the bad, and the target Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Lena Cords, Natalie de Souza, Bernd Bodenmiller
Cancer-associated fibroblasts (CAFs) are heterogeneous and ubiquitous stromal cells within the tumor microenvironment (TME). Numerous CAF types have been described, typically using single-cell technologies such as single-cell RNA sequencing. There is no general classification system for CAFs, hampering their study and therapeutic targeting. We propose a simple CAF classification system based on single-cell
-
Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Anthony R. Cillo, John M. Kirkwood
Combination immunotherapy improves outcomes in metastatic melanoma, but the underlying mechanisms remain unclear. In this issue of Cancer Cell, Wang et al.1 report dynamics and transcriptional states of CD8+ T cell clones over time in patients treated with anti-PD-1, anti-CTLA-4, or a combination of the two. These findings have important implications for understanding and monitoring combination immunotherapy
-
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Spencer S. Watson, Anoek Zomer, Nadine Fournier, Joao Lourenco, Manfredo Quadroni, Agnieszka Chryplewicz, Sina Nassiri, Pauline Aubel, Simona Avanthay, Davide Croci, Erik Abels, Marike L.D. Broekman, Douglas Hanahan, Jason T. Huse, Roy T. Daniel, Monika E. Hegi, Krisztian Homicsko, Giulia Cossu, Andreas F. Hottinger, Johanna A. Joyce
-
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Meeki Lad, Angad S. Beniwal, Saket Jain, Poojan Shukla, Venina Kalistratova, Jangham Jung, Sumedh S. Shah, Garima Yagnik, Atul Saha, Ankita Sati, Husam Babikir, Alan T. Nguyen, Sabraj Gill, Jennifer Rios, Jacob S. Young, Austin Lui, Diana Salha, Aaron Diaz, Manish K. Aghi
-
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Jiachen Xu, Rui Wan, Yiran Cai, Shangli Cai, Lin Wu, Baolan Li, Jianchun Duan, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu
-
Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma Cancer Cell (IF 48.8) Pub Date : 2024-09-05 Rachel N. Curry, Qianqian Ma, Malcolm F. McDonald, Yeunjung Ko, Snigdha Srivastava, Pey-Shyuan Chin, Peihao He, Brittney Lozzi, Prazwal Athukuri, Junzhan Jing, Su Wang, Arif O. Harmanci, Benjamin Arenkiel, Xiaolong Jiang, Benjamin Deneen, Ganesh Rao, Akdes Serin Harmanci
-
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant Cancer Cell (IF 48.8) Pub Date : 2024-09-03 Ilon Liu, Gustavo Alencastro Veiga Cruzeiro, Lynn Bjerke, Rebecca F. Rogers, Yura Grabovska, Alexander Beck, Alan Mackay, Tara Barron, Olivia A. Hack, Michael A. Quezada, Valeria Molinari, McKenzie L. Shaw, Marta Perez-Somarriba, Sara Temelso, Florence Raynaud, Ruth Ruddle, Eshini Panditharatna, Bernhard Englinger, Hafsa M. Mire, Li Jiang, Andrezza Nascimento, Jenna LaBelle, Rebecca Haase, Jacob Rozowsky
-
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Christopher A. Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L. Savage, Serena Muratcioglu, Noah Merz, Richard D. Press, Thomas O’Hare, Thomas Jacob, Tania Q. Vu, Cristina E. Tognon, Tara A. Macey, John Kuriyan, Charalampos G. Kalodimos, Brian J. Druker
No Abstract
-
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Ashwin Somasundaram, Hanna K. Sanoff
Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy has demonstrated efficacy in combination with radiation. In this issue, Xiao et al. demonstrate promising efficacy with the addition of PD-1 blockade to neoadjuvant therapy for mismatch-repair proficient rectal cancer.
-
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Itay Tirosh, Mario L. Suva
Human tumors are intricate ecosystems composed of diverse genetic clones and malignant cell states that evolve in a complex tumor micro-environment. Single-cell RNA-sequencing (scRNA-seq) provides a compelling strategy to dissect this intricate biology and has enabled a revolution in our ability to understand tumor biology over the last ten years. Here we reflect on this first decade of scRNA-seq in
-
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth Seier, Gun Ho Jang, Henry Walch, Victoria G. Aveson, David J. Falvo, William B. Fall, Christopher W. Chan, Andrew Wenger, Brett L. Ecker, Alessandra Pulvirenti, Rebecca Gelfer, Maria Paz Zafra, Nikolaus Schultz, Wungki Park, Eileen M. O’Reilly, Shauna L. Houlihan, Alicia Alonso, Erika Hissong, George M. Church,
-
Precision oncology across the ages: Impact on children, adolescents, and young adults Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Vivek Subbiah, Razelle Kurzrock
Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups. In this commentary, we review the application of precision oncology across different age groups, specifically in children, adolescents, and young adults, and emphasize that precision medicine is age and tissue agnostic
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Luigi Perelli, Giannicola Genovese, Giulio F. Draetta
In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRASG12R mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.
-
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar, Sabrina Solis, Ajeya Nandi, Shaneaka Anderson, Nicholas Han, Sasikanth Manne, Evgeny Kiner, Chirag Sachar, Minke Lucas, Sangeeth George, Patrick K. Yan, Melanie W. Kier, Amy I. Laughlin, Shawn Kothari, Josephine Giles, Divij Mathew, Reem Ghinnagow, Cecile Alanio, Ahron Flowers, Wei Xu, Daniel J. Tenney, Xiaowei Xu, Ravi K. Amaravadi
-
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma Cancer Cell (IF 48.8) Pub Date : 2024-08-15 Clémentine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana B. Neriah, Katy Milne, Talia Goodyear, Celia Strong, Tashi Rastogi, Laura K. Hilton, Daniel Lai, Laurie H. Sehn, Pedro Farinha, Brad H. Nelson, Andrew Weng, Marco Marra, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth
No Abstract
-
Leading medulloblastoma to a differentiation end Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Carolina Nör, Vijay Ramaswamy
Effective and less toxic therapies for medulloblastoma have proved to be highly elusive. In this issue of Cancer Cell, Yang et al. show that thyroid hormone treatment leads to the activation of neurogenic differentiation factor 1 (NeuroD1) and differentiation of medulloblastoma cells through reversing EZH2-mediated transcriptional repression of NeuroD1.
-
When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21 Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Nicholas D. Huntington
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
-
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Yifan Zhang, Guangjian Liu, Qianwen Zeng, Wenrui Wu, Kai Lei, Chuankai Zhang, Miaoling Tang, Yuting Zhang, Xiao Xiang, Li Tan, Rui Cui, Si Qin, Xinming Song, Changjun Yin, Zhihang Chen, Ming Kuang
-
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Yang Sun, Xiang Zhang, Dong Hang, Harry Cheuk-Hay Lau, Jie Du, Chuanfa Liu, Mingxu Xie, Yasi Pan, Le Wang, Cong Liang, Xingyu Zhou, Danyu Chen, Jiamei Rong, Zengren Zhao, Alvin Ho-Kwan Cheung, Yuet Wu, Hongyan Gou, Chi Chun Wong, Lingbin Du, Junliang Deng, Zhibin Hu, Hongbing Shen, Yinglei Miao, Jun Yu
-
Thyroid hormone suppresses medulloblastoma progression through promoting terminal differentiation of tumor cells Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Yijun Yang, Silvia Anahi Valdés-Rives, Qing Liu, Tong Gao, Chakkapong Burudpakdee, Yuzhe Li, Jun Tan, Yinfei Tan, Christian A. Koch, Yuan Rong, Steven R. Houser, Shuanzeng Wei, Kathy Q. Cai, Jinhua Wu, Sheue-yann Cheng, Robert Wechsler-Reya, Zeng-jie Yang
-
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Mayra Shanley, May Daher, Jinzhuang Dou, Sufang Li, Rafet Basar, Hind Rafei, Merve Dede, Joy Gumin, Jezreel Pantaleόn Garcίa, Ana Karen Nunez Cortes, Shan He, Corry M. Jones, Sunil Acharya, Natalie W. Fowlkes, Donghai Xiong, Sanjay Singh, Hila Shaim, Samantha Claire Hicks, Bin Liu, Abhinav Jain, Mohammad Fayyad Zaman, Qi Miao, Ye Li, Nadima Uprety, Enli Liu, Luis Muniz-Feliciano, Gary M. Deyter, Vakul
Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple models, IL-21 NK cells were superior to IL-15 NK cells both in terms
-
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Jan D. Beck, Mustafa Diken, Martin Suchan, Michael Streuber, Elif Diken, Laura Kolb, Lisa Allnoch, Fulvia Vascotto, Daniel Peters, Tim Beißert, Özlem Akilli-Öztürk, Özlem Türeci, Sebastian Kreiter, Mathias Vormehr, Ugur Sahin
No Abstract
-
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Xiaoju Wang, Yuanyuan Qiao, Irfan A. Asangani, Bushra Ateeq, Anton Poliakov, Marcin Cieślik, Sethuramasundaram Pitchiaya, Balabhadrapatruni V.S.K. Chakravarthi, Xuhong Cao, Xiaojun Jing, Cynthia X. Wang, Ingrid J. Apel, Rui Wang, Jean Ching-Yi Tien, Kristin M. Juckette, Wei Yan, Hui Jiang, Shaomeng Wang, Sooryanarayana Varambally, Arul M. Chinnaiyan
No Abstract
-
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial Cancer Cell (IF 48.8) Pub Date : 2024-08-01 Wei-Wei Xiao, Gong Chen, Yuan-Hong Gao, Jun-Zhong Lin, Xiao-Jun Wu, Hui-Long Luo, Zhen-Hai Lu, Qiao-Xuan Wang, Rui Sun, Pei-Qiang Cai, Chong-Mei Zhu, Min Liu, Ji-Bin Li, Yi-Rui Wang, Ying Jin, Feng Wang, Hai-Tao Luo, Cai-Ling Li, Zhi-Zhong Pan, Rui-Hua Xu
-
CAR T cell combination therapies to treat cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-25 Ugur Uslu, Sofia Castelli, Carl H. June
Chimeric antigen receptor (CAR) T cells are effectively used in certain hematological malignancies, though tumor relapse and limited success in solid …
-
Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study Cancer Cell (IF 48.8) Pub Date : 2024-07-25 Jiawei Lv, Ling-Xin Xu, Zhi-Xuan Li, Li Lin, Chen-Fei Wu, Ting-Qiu Quan, Zi-Cheng Zhen, Wen-Fei Li, Ling-Long Tang, Yan-Ping Mao, Lei Chen, Rui Guo, Lu-Lu Zhang, Xin-Lei Ai, Shi-Yue Wu, Meng-Yu Hao, Denghui Wei, Ji-Bin Li, Jun Ma, Yu-Pei Chen, Guan-Qun Zhou, Ying Sun
-
Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of immunosuppression in cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Carolina Mangana, Barbara B. Maier
Dendritic cells are critical inducers of adaptive anti-tumor immunity. However, their maturation, activation, and migration are often compromised in the tumor microenvironment. In this issue, You et al. demonstrate a novel axis of suppression of dendritic cell function mediated by interaction with regulatory T cells in perilymphatic niches.
-
Transcription factor dependencies identify BAF-dependent cancers Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Helen M. McRae, Diana C. Hargreaves
In Cancer Cell, Bolomsky et al., Duplaquet et al., and He et al. identify cancers that are dependent on the BAF chromatin remodeling complex, specifically IRF4-driven multiple myeloma and POU2F3-subtype small cell lung cancer, highlighting potential therapeutic applications for BAF complex inhibitors/degraders.
-
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Tongchen He, Lanbo Xiao, Yuanyuan Qiao, Olaf Klingbeil, Eleanor Young, Xiaoli S. Wu, Rahul Mannan, Somnath Mahapatra, Esther Redin, Hanbyul Cho, Yi Bao, Malathi Kandarpa, Jean Ching-Yi Tien, Xiaoju Wang, Sanjana Eyunni, Yang Zheng, NamHoon Kim, Heng Zheng, Siyu Hou, Fengyun Su, Stephanie J. Miner, Rohit Mehra, Xuhong Cao, Chandrasekhar Abbineni, Susanta Samajdar, Murali Ramachandra, Saravana M. Dhanasekaran
-
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Leslie Duplaquet, Kevin So, Alexander W. Ying, Shreoshi Pal Choudhuri, Xinyue Li, Grace D. Xu, Yixiang Li, Xintao Qiu, Rong Li, Shilpa Singh, Xiaoli S. Wu, Seth Hamilton, Victor D. Chien, Qi Liu, Jun Qi, Tim D.D. Somerville, Hillary M. Heiling, Emanuele Mazzola, Yenarae Lee, Thomas Zoller, Christopher R. Vakoc, John G. Doench, William C. Forrester, Tinya Abrams, Henry W. Long, Matthew J. Niederst,
-
Tumor-infiltrating lymphocytes: A new hope Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Amod A. Sarnaik, Patrick Hwu, James J. Mulé, Shari Pilon-Thomas
Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved
-
Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity Cancer Cell (IF 48.8) Pub Date : 2024-07-18 Siyuan You, Shuqin Li, Lingsu Zeng, Jinsheng Song, Zifeng Li, Weiyun Li, Hengxiao Ni, Xu Xiao, Wenbo Deng, Hongye Li, Wenbo Lin, Chenyu Liang, Yanfei Zheng, Shih-Chin Cheng, Nengming Xiao, Mengsha Tong, Rongshan Yu, Jialiang Huang, Hongling Huang, Hongzhi Xu, Jiahuai Han, Jianlin Ren, Kairui Mao
-
Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Veronica Lise, Ines Malenica, Rahul Roychoudhuri, Enrico Lugli
In this issue of Cancer Cell, Espinosa-Carrasco et al. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4+ and CD8+ T cells. This interaction reprograms tumor-specific CD8+ T cells to exert potent effector functions and eradicate established solid tumors.
-
Medulloblastoma subgrouping at first sight Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Marc Remke, Vijay Ramaswamy
Recent incorporation of the four primary medulloblastoma subgroups into the WHO Classification of Central Nervous System Tumors necessitates globally accessible methods to discern subgroups. In this issue of Cancer Cell, Wang et al. develop a rapid and reliable machine learning workflow for pre-operative subgroup determination using routine magnetic resonance imaging.
-
HRS-4642: The next piece of the puzzle to keep KRAS in check Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Alejandra A. Flores-Gómez, Matthias Drosten
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows pote…
-
Casting a wider net: The clinical potential of EV transcriptomics in multi-analyte liquid biopsy Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yari Ciani, Caterina Nardella, Francesca Demichelis
Cancer cells release cell-free DNA (cfDNA) and extracellular vesicles (EVs) into the bloodstream, allowing disease non-invasive monitoring. In this issue of Cancer Cell, Casanova-Salas et al. analyze cfDNA, EV-DNA, and EV-RNA in prostate cancer longitudinal cohorts treated with androgen receptor signaling inhibitors and taxanes, identifying signals reflecting tumor adaptation processes.
-
Multi-scale signaling and tumor evolution in high-grade gliomas Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Jingxian Liu, Song Cao, Kathleen J. Imbach, Marina A. Gritsenko, Tung-Shing M. Lih, Jennifer E. Kyle, Tomer M. Yaron-Barir, Zev A. Binder, Yize Li, Ilya Strunilin, Yi-Ting Wang, Chia-Feng Tsai, Weiping Ma, Lijun Chen, Natalie M. Clark, Andrew Shinkle, Nataly Naser Al Deen, Wagma Caravan, Andrew Houston, Faria Anjum Simin, Matthew A. Wyczalkowski, Liang-Bo Wang, Erik Storrs, Siqi Chen, Ritvik Illindala
-
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yuqing Chen, Dongfang Wang, Yingjie Li, Lu Qi, Wen Si, Yufei Bo, Xueyan Chen, Zhaochen Ye, Hongtao Fan, Baolin Liu, Chang Liu, Li Zhang, Xiaoyan Zhang, Zhongwu Li, Linna Zhu, Aiwen Wu, Zemin Zhang
-
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Irene Casanova-Salas, Daniel Aguilar, Sarai Cordoba-Terreros, Laura Agundez, Julian Brandariz, Nicolas Herranz, Alba Mas, Macarena Gonzalez, Rafael Morales-Barrera, Alexandre Sierra, Mario Soriano-Navarro, Pablo Cresta, Gisela Mir, Sara Simonetti, Gonçalo Rodrigues, Sara Arce-Gallego, Luisa Delgado-Serrano, Irene Agustí, Elena Castellano-Sanz, Richard Mast, Matias de Albert, Ana Celma, Anna Santamaria
-
Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yong Lu, Qiang Wang, Gang Xue, Enguang Bi, Xingzhe Ma, Aibo Wang, Jianfei Qian, Chen Dong, Qing Yi
No Abstract
-
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer Cancer Cell (IF 48.8) Pub Date : 2024-06-27 Caicun Zhou, Chongyang Li, Libo Luo, Xin Li, Keyi Jia, Ning He, Shiqi Mao, Wanying Wang, Chuchu Shao, Xinyu Liu, Kan Huang, Yaxin Yu, Xinlei Cai, Yingxue Chen, Zican Dai, Wei Li, Jia Yu, Jiayu Li, Feng Shen, Zaiyong Wang, Feng He, Xing Sun, Rongfu Mao, Wei Shi, Jun Zhang, Tao Jiang, Zhe Zhang, Fei Li, Shengxiang Ren
-
Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures Cancer Cell (IF 48.8) Pub Date : 2024-06-27 Yan-Ran (Joyce) Wang, Pengcheng Wang, Zihan Yan, Quan Zhou, Fatma Gunturkun, Peng Li, Yanshen Hu, Wei Emma Wu, Kankan Zhao, Michael Zhang, Haoyi Lv, Lehao Fu, Jiajie Jin, Qing Du, Haoyu Wang, Kun Chen, Liangqiong Qu, Keldon Lin, Michael Iv, Hao Wang, Xiaoyan Sun, Hannes Vogel, Summer Han, Lu Tian, Feng Wu, Jian Gong
-
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Arnold Bolomsky, Michele Ceribelli, Sebastian Scheich, Kristina Rinaldi, Da Wei Huang, Papiya Chakraborty, Lisette Pham, George W. Wright, Tony Hsiao, Vivian Morris, Jaewoo Choi, James D. Phelan, Ronald J. Holewinski, Thorkell Andresson, Jan Wisniewski, Deanna Riley, Stefania Pittaluga, Elizabeth Hill, Craig J. Thomas, Jagan Muppidi, Ryan M. Young
-
How can we integrate the biology of breast cancer cell dormancy into clinical practice? Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Islam E. Elkholi, April A.N. Rose, Julio A. Aguirre-Ghiso, Jean-François Côté
Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these approaches do not consider emerging fundamentals in the biology of metastatic dormancy and relapse. Conversely, the field of metastatic dormancy often discounts key clinical factors
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D. Hellmann, Bryan M. Burt, Hyun-Sung Lee, Andrea Schietinger
-
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Qing Zhou, Yi Pan, Xuening Yang, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Li Song, Wei Shi, Yi-Long Wu
-
Bacteria in metastatic sites: Unveiling hidden players in cancer progression Cancer Cell (IF 48.8) Pub Date : 2024-06-13 Philippe Stevens, Elena Benidovskaya, Veronica Llorens-Rico, Jeroen Raes, Marc Van Den Eynde
Bacteria exhibit key features of cancer metastasis, such as motility, invasion, and modulation of the tumor microenvironment. They migrate through lymphatic and blood systems, invade metastatic tissues, and alter local microenvironments to support metastatic growth. Bacteria also shape the tumor microenvironment, affecting immune responses and inflammation, which influence tumor progression and therapy
-
Artificial intelligence Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Moritz Gerstung, David Liu, Marzyeh Ghassemi, James Zou, Diego Chowell, Jonas Teuwen, Faisal Mahmood, Jakob Nikolas Kather
Experts discuss the challenges and opportunities of using artificial intelligence (AI) to study the evolution of cancer cells and their microenvironment, improve diagnosis, predict treatment response, and ensure responsible implementation in the clinic.
-
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, David M. Thomas, Hans Gelderblom
Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment
-
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Robert Saddawi-Konefka, Shiruyeh Schokrpur, J. Silvio Gutkind
Solid cancers often progress via metastasis to lymph nodes. Consequently, lymphadenectomy is central to stage cancers and eradicates disease spread. However, mounting evidence suggests that cancer immunotherapies drive antitumor immune responses within lymph nodes. This implies that immunotherapy, delivered with standard oncologic therapies, may require specific treatment sequencing to initiate immunosurveillance
-
Mapping myeloid cell function: Spatial diversity in tumor and neuronal microenvironment Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Giulia Villa, Daniel Delev, Dieter Henrik Heiland
In this issue of Cancer Cell, Zhong et al. explore the dual role of TREM2 in glioblastoma-associated myeloid cells, demonstrating its function in promoting inflammation at the tumor-neural interface and suppression within the tumor core, influenced by the local microenvironment. These findings open up promising prospects for advancements in neuro-oncological immunotherapy.
-
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Abir Hussein, Slava Stamova, Maria Xydia, Philipp Beckhove
Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show that effective immunotherapy requires a series of processes orchestrated by CD8+ T cells that result in the recruitment and local activation of M1-like macrophages.
-
Breaking up the CD8+ T cell: Treg pas de deux Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Chenyu Zhang, Alissa Bockman, Michel DuPage
Checkpoint blockade immunotherapies, such as anti-programmed death-1 (PD-1), unleash anti-tumor CD8+ T cell responses but may also induce immunosuppressive regulatory T cells (Tregs). In this issue of Cancer Cell, Geels et al. uncover that anti-PD-1 leads to Treg expansion via interleukin-2 (IL-2)-producing CD8+ T cells. Combining anti-PD-1 with anti-ICOSL interrupts this crosstalk, thereby enhancing
-
Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Naiara Perurena, Karen Cichowski
The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in Nature and Cancer Discovery describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while